The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program

By sjmartinez • April 27, 2025

Hanauer SB, Torres EA, Aragon-Han P, Chapman JC, Swaminath AC, Arai R, Butnariu M, Lee TC, Rabizadeh S, Check M, Barrett TA, Hashash JG, Meister T, Yen EF, Kinnucan J, Stein DJ, Ziring D, Shaposhnikov R, Sinh P, Qazi TM, Yarur AJ, Monzur F, Dervieux T, Abraham BP. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics. 2025 Mar 27;17(4):428. doi: 10.3390/pharmaceutics17040428. PMID: 40284422; PMCID: PMC12030419.

Tags: adalimumab, Cedars Sinai DoM, clearance, Digestive Diseases, dose optimization, inflammatory bowel disease, pharmacokinetics; precision medicine, precision-guided dosing, Publications, real-world data, therapeutic drug monitoring

Deep Learning with Domain Randomization in Image and Feature Spaces for Abdominal Multiorgan Segmentation on CT and MRI Scans

Shi Y, Wang L, Qureshi TA, Deng Z, Xie Y, Li D. Deep Learning with Domain Randomization in Image and Feature Spaces for Abdominal Multiorgan[...]

Accelerating CEST MRI With Deep Learning-Based Frequency Selection and Parameter Estimation

Shen C, Cheema K, Xie Y, Ruan D, Li D. Accelerating CEST MRI With Deep Learning-Based Frequency Selection and Parameter Estimation. NMR Biomed. 2025 Jul;38(7):e70068.[...]

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC,[...]